LVW Advisors LLC Purchases 9,223 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

LVW Advisors LLC increased its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 56.4% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 25,580 shares of the biopharmaceutical company’s stock after acquiring an additional 9,223 shares during the period. LVW Advisors LLC’s holdings in Gilead Sciences were worth $1,874,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of GILD. Altfest L J & Co. Inc. bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $210,000. Federated Hermes Inc. grew its position in shares of Gilead Sciences by 4.9% in the 4th quarter. Federated Hermes Inc. now owns 3,787,355 shares of the biopharmaceutical company’s stock valued at $306,814,000 after buying an additional 175,925 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Gilead Sciences by 1.2% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 7,281,489 shares of the biopharmaceutical company’s stock valued at $589,873,000 after purchasing an additional 87,482 shares during the period. Wetzel Investment Advisors Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at about $74,000. Finally, Eagle Asset Management Inc. lifted its stake in shares of Gilead Sciences by 23.6% in the 4th quarter. Eagle Asset Management Inc. now owns 317,539 shares of the biopharmaceutical company’s stock valued at $25,724,000 after purchasing an additional 60,697 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on GILD. Royal Bank of Canada reissued a “sector perform” rating and issued a $74.00 price objective on shares of Gilead Sciences in a research note on Friday, June 14th. UBS Group dropped their price objective on Gilead Sciences from $81.00 to $75.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 17th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Barclays dropped their price objective on Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Finally, StockNews.com raised Gilead Sciences from a “buy” rating to a “strong-buy” rating in a research note on Saturday, April 27th. Twelve research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Hold” and an average price target of $83.47.

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $68.61 on Monday. The company has a market cap of $85.48 billion, a PE ratio of 190.58, a price-to-earnings-growth ratio of 2.92 and a beta of 0.18. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The business has a 50 day moving average price of $65.98 and a 200-day moving average price of $72.51. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($1.32) EPS for the quarter, topping the consensus estimate of ($1.49) by $0.17. The firm had revenue of $6.69 billion during the quarter, compared to the consensus estimate of $6.36 billion. Gilead Sciences had a return on equity of 24.34% and a net margin of 1.76%. The company’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same period in the prior year, the business posted $1.37 earnings per share. Equities analysts anticipate that Gilead Sciences, Inc. will post 3.75 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, June 27th. Stockholders of record on Friday, June 14th were issued a $0.77 dividend. This represents a $3.08 annualized dividend and a dividend yield of 4.49%. The ex-dividend date was Friday, June 14th. Gilead Sciences’s dividend payout ratio is presently 855.56%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.